Newcourt (NASDAQ:NCAC) announced in an 8-K this morning that it has secured an aggregate of $12.5 million in convertible notes for its merger with psychedelic medicine company Psyence (CSE:PSYG).
The notes will consist of up to four senior secured convertible notes, issuable to the purchaser at or after the closing, in exchange for up to $10 million in subscription amounts.
The issuance of the tranche notes each involves a principal amount of $3.12 million in exchange for subscription amounts totaling $2.5 million.
While the first tranche note is contingent upon the completion of the combination with Psyence, the second tranche note allows for adjustments based on the market value traded. The purchaser may invest additional amounts over time to fulfill the second tranche note.
The third and fourth tranche notes, if issued, follow a similar structure with a principal of $3.12 million exchanged for $2.5 million in subscription amounts.
Interest will begin accruing at 8.0% per annum based on the outstanding principal amount of the note, payable monthly in cash or common shares.
Additionally, in consideration of the willingness of the purchaser, shareholders will deliver a structuring fee of common shares with 1.3 million structuring shares delivered at the first tranche closing. Following the closing, 1.7 million structuring shares will be delivered under the terms outlined in the call option agreements to be entered into between the purchaser and certain shareholders.
In connection with the securities purchase agreement, the sponsor and Psyence Group will enter into a lock-up agreement for 180 days following the closing of the combination.
Furthermore, the parties agreed to waive the minimum cash closing condition of $20 million and the investment condition stating that the PIPE should be ready to occur concurrently with the closing.
Newcourt announced its deal with Psyence in January 2023. As of now, the SPAC faces a completion deadline of January 22, but is looking to hold a shareholder meeting to extend its timeline. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.
At the SPAC of Dawn As we close out Passover and head into Easter weekend, we’re reminded that even the most hopeless situations, like wandering the desert for 40 years, being dead for three days, or trying to close a DeSPAC with zero redemptions in this market, can eventually turn around. After all, SPACs have...
Globa Terra Acquisition Corporation (NASDAQ:GTERU) has filed for a $152.2 million SPAC to find an agriculture or food-tech target company The new SPAC is overfunded to 100.5% and is set to have both a 3/4 warrant and right to a 1/20 share in each of its units. This vies for the most investor-friendly unit coverage of...
EGH Acquisition Corp. (NASDAQ:EGHAU) has filed for a $150 million SPAC to continue the work of the Tortoise serial SPAC team under a fresh name. The new SPAC is not overfunded and will have one right to a 1/10 share in each of its units. It will have 24 months to initially close a business...
Yorkville Acquisition Corp. has filed for a $150 million SPAC to bring the sponsor’s experience in SPAC investing to a search for a technology, media or telecom target. The new SPAC is overfunded to 100.5% with $10.05 per unit in trust initially. Each unit is set to contain a 1/3 share and it will have...
At the SPAC of Dawn This week’s trading comes to an end later today as the US exchanges will observe the Good Friday holiday (but the SEC’s EDGAR filing system will not). Dow futures ahead of this session remain in the red although both the S&P 500 and Nasdaq look to make up some losses...